Targeting Cancer Stem Cells to Overcome Therapy Resistance: Mechanisms, Biomarkers, and Clinical Translation
Deadline 2026-10-31Taylor & FrancisIndexed (Active)
Journal: Cancer Management and Research
Cancer stem cells (CSCs) are a therapy-resistant subpopulation that drives tumor initiation, progression, metastasis, and recurrence. Their capacity for self-renewal, plasticity, and adaptation underpins resistance to chemotherapy, radiotherapy, and immunotherapy, making them a central obstacle to long-term therapeutic success. Eradicating CSCs is thus recognized as a critical goal in improving long-term patient sur…
Advances in Dietary and Metabolic Interventions for Cancer Care
Deadline 2027-04-01Taylor & FrancisIndexed (Active)
Journal: Cancer Management and Research
Dietary and metabolic interventions are increasingly recognized as important adjuncts in the management of cancer. Recent research has demonstrated that approaches such as ketogenic diets, Mediterranean Diets, fasting protocols, and whole-foods dietary patterns can influence cancer biology, treatment outcomes, and patient well-being. These strategies are not only relevant for symptom management but also for addressi…
Artificial Intelligence and Multi-Omics in Precision Oncology: From Biomarker Discovery to Translational Therapeutics
Deadline 2027-05-01Taylor & FrancisIndexed (Active)
Journal: Cancer Management and Research
Recent advances in artificial intelligence (AI), single-cell and spatial omics, digital pathology, radiomics, and computational biology are transforming the landscape of precision oncology. These technologies have enabled unprecedented opportunities for deciphering tumor heterogeneity, identifying clinically relevant biomarkers, predicting therapeutic responses, and discovering novel targets for personalized treatme…
Beyond Cystectomy: New Approaches in Bladder Cancer Diagnosis and Treatment
Deadline 2027-05-01Taylor & FrancisIndexed (Active)
Journal: Cancer Management and Research
Bladder cancer remains a significant global health burden, characterized by high recurrence rates and the need for lifelong surveillance. While radical cystectomy has long been the standard of care for muscle-invasive disease, it comes with substantial morbidity and a profound impact on patients' quality of life. This Article Collection seeks to highlight the paradigm shift occurring in the field, moving beyond trad…
Pulmonary Toxicities of Cancer Therapies
Deadline 2027-05-01Taylor & FrancisIndexed (Active)
Journal: Cancer Management and Research
Pulmonary toxicities are increasingly recognized as major complications associated with modern cancer therapies. The expanding use of immune checkpoint inhibitors, molecular targeted therapies, antibody-drug conjugates, radiation therapy, and combination regimens has improved survival outcomes across multiple malignancies; however, these advances have also led to an increasing incidence of treatment-related pulmonar…
Reference integrity note: verify every citation against the original source before submission, including publication year, journal title, volume/issue, page range, DOI, and the target journal style.
DrAIStudio